NCT03937895View on ClinicalTrials.gov

"Allogeneic NK Cell (SMT-NK) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer"

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
Biliary Tract Cancer
Interventions
BIOLOGICAL

'SMT-NK' Inj (allogeneic Natural Killer cell)

In 120 mL, 3x10\^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.

DRUG

Pembrolizumab Injection [Keytruda]

Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).

Trial Locations (2)

03722

Severance Hospital, Seoul

06273

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

SMT bio Co., Ltd.

INDUSTRY

NCT03937895 - "Allogeneic NK Cell (SMT-NK) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer" | Biotech Hunter | Biotech Hunter